Royal Bank Of Canada Ventyx Biosciences, Inc. Transaction History

Royal Bank Of Canada

$471 Billion
Q3 2024

A detailed history of Royal Bank Of Canada transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 6,363 shares of VTYX stock, worth $14,825. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,363

Previous 5,716 11.32%

Holding current value

$14,825

Previous $13,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.85 - $3.2 $1,196 - $2,070	647 Added 11.32%	6,363 $13,000
Q2 2024 Aug 14, 2024	SELL	$2.31 - $5.59 $2,016 - $4,880	-873 Reduced 13.25%	5,716 $13,000
Q1 2024 Nov 05, 2024	BUY	$1.9 - $10.13 $1,658 - $8,843	873 Added 15.27%	6,589 $36,000
Q1 2024 May 15, 2024	SELL	$1.9 - $10.13 $85,847 - $457,703	-45,183 Reduced 87.27%	6,589 $36,000
Q4 2023 Feb 14, 2024	BUY	$2.08 - $31.18 $95,499 - $1.43 Million	45,913 Added 783.63%	51,772 $127,000
Q3 2023 Nov 14, 2023	SELL	$29.8 - $40.3 $199,481 - $269,768	-6,694 Reduced 53.33%	5,859 $203,000
Q2 2023 Aug 14, 2023	BUY	$28.53 - $39.55 $318,366 - $441,338	11,159 Added 800.5%	12,553 $411,000
Q1 2023 May 15, 2023	SELL	$29.51 - $46.65 $58,695 - $92,786	-1,989 Reduced 58.79%	1,394 $46,000
Q4 2022 Feb 14, 2023	SELL	$24.16 - $36.38 $54,094 - $81,454	-2,239 Reduced 39.83%	3,383 $110,000
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $69,456 - $212,656	5,495 Added 4326.77%	5,622 $197,000
Q2 2022 Aug 15, 2022	SELL	$11.95 - $18.75 $6,142 - $9,637	-514 Reduced 80.19%	127 $2,000
Q1 2022 May 16, 2022	SELL	$10.0 - $19.98 $14,400 - $28,771	-1,440 Reduced 69.2%	641 $9,000
Q4 2021 Feb 14, 2022	BUY	$14.2 - $23.07 $29,550 - $48,008	2,081 New	2,081 $41,000

Others Institutions Holding VTYX

# of Institutions

125

Shares Held

52.9M

Call Options Held

35.3K

Put Options Held

83K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $132M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Ventyx Biosciences, Inc. Transaction History